Stay updated with breaking news from Christopher Posner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease -associated pruritus in adult... | June 11, 2023
A small molecule drug has been recommended by England’s National Institute for Health Care and Excellence (NICE) for the treatment of adults with moderate to severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis.
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) CEO Christopher Posner sold 3,869 shares of the company’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $4.40, for a total value of $17,023.60. Following the transaction, the chief executive officer now directly owns 172,514 shares in the company, […]
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 4,840,000 shares, a decline of 9.4% from the March 31st total of 5,340,000 shares. Based on an average daily volume of 642,000 shares, the […]
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $9.31 and traded as low as $3.90. Cara Therapeutics shares last traded at $3.93, with a volume of 511,942 shares changing hands. Analyst […]